<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-11-18" updated="2020-01-02">
  <drugbank-id primary="true">DB05273</drugbank-id>
  <name>Samarium (153Sm) lexidronam</name>
  <description>Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.</description>
  <cas-number>122575-21-7</cas-number>
  <unii>745X144DZY</unii>
  <average-mass>586.021</average-mass>
  <monoisotopic-mass>585.895290894</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3333</ref-id>
        <pubmed-id>17167764</pubmed-id>
        <citation>Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ: Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007 Feb 1;109(3):637-43.</citation>
      </article>
      <article>
        <ref-id>A3334</ref-id>
        <pubmed-id>10983757</pubmed-id>
        <citation>Menda Y, Bushnell DL, Williams RD, Miller S, Thomas MO: Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin Nucl Med. 2000 Sep;25(9):698-700.</citation>
      </article>
      <article>
        <ref-id>A18899</ref-id>
        <pubmed-id>20864370</pubmed-id>
        <citation>Vigna L, Matheoud R, Ridone S, Arginelli D, Della Monica P, Rudoni M, Inglese E, Brambilla M: Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis. Phys Med. 2011 Jul;27(3):144-52. doi: 10.1016/j.ejmp.2010.08.001. Epub 2010 Sep 23.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>Samarium Sm 153 lexidronam targets the sites of new bone formation, concentrating in regions of the bone that have been invaded with metastatic tumor. The drug goes to the source of cancer bone pain and irradiates the osteoblastic tumor sites resulting in relief of pain. The onset of pain relief was experienced as early as one week in the majority of patients.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002635</drugbank-id>
      <name>Samarium (153Sm) lexidronam pentasodium</name>
      <unii>7389YR3OOV</unii>
      <cas-number>176669-18-4</cas-number>
      <inchikey>SZZACTGRBZTAKY-NKNBZPHVSA-F</inchikey>
      <average-mass>695.93</average-mass>
      <monoisotopic-mass>695.80501213</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">153SM-EDTMP</synonym>
    <synonym language="english" coder="">Samarium (153 Sm) lexidronam</synonym>
    <synonym language="english" coder="inn">Samarium (153Sm) lexidronam</synonym>
    <synonym language="english" coder="">Samarium Sm-153 lexidronam</synonym>
    <synonym language="english" coder="">Samarium-153 lexidronam</synonym>
    <synonym language="english" coder="">Samarium-153-EDTMP</synonym>
  </synonyms>
  <products>
    <product>
      <name>Quadramet</name>
      <labeller>Lantheus Medical Imaging</labeller>
      <ndc-id/>
      <ndc-product-code>11994-016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-05-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020570</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quadramet</name>
      <labeller>Cytogen Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>50419-209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-01</started-marketing-on>
      <ended-marketing-on>2006-06-01</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>50 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quadramet</name>
      <labeller>Jazz Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57902-860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-01</started-marketing-on>
      <ended-marketing-on>2013-07-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020570</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Quadramet</name>
      <ingredients>Samarium (153Sm) lexidronam</ingredients>
    </mixture>
    <mixture>
      <name>Quadramet</name>
      <ingredients>Samarium (153Sm) lexidronam</ingredients>
    </mixture>
    <mixture>
      <name>Quadramet</name>
      <ingredients>Samarium (153Sm) lexidronam</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Analgesics</category>
      <mesh-id>D000700</mesh-id>
    </category>
    <category>
      <category>Analgesics, Non-Narcotic</category>
      <mesh-id>D018712</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Pain Palliation (Bone Seeking Agents)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Radioactive Therapeutic Agent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Radioisotopes</category>
      <mesh-id>D011868</mesh-id>
    </category>
    <category>
      <category>Radiopharmaceutical Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sensory System Agents</category>
      <mesh-id>D018689</mesh-id>
    </category>
    <category>
      <category>Therapeutic Radiopharmaceuticals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Various Pain Palliation Radiopharmaceuticals</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>50 mCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Intravenous</route>
      <strength>50 mCi/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V10BX02">
      <level code="V10BX">Various pain palliation radiopharmaceuticals</level>
      <level code="V10B">PAIN PALLIATION (BONE SEEKING AGENTS)</level>
      <level code="V10">THERAPEUTIC RADIOPHARMACEUTICALS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.03</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.00e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-4.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(153Sm)samarium(3+) ion hydrogen {[(hydrogen phosphonomethyl)({2-[(hydrogen phosphonomethyl)(phosphonomethyl)amino]ethyl})amino]methyl}phosphonate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(153Sm)samarium(3+) ion hydrogen [(hydrogen phosphonomethyl)({2-[(hydrogen phosphonomethyl)(phosphonomethyl)amino]ethyl})amino]methylphosphonate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>586.021</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>585.895290894</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[153Sm+3].OP(O)(=O)CN(CCN(CP(O)([O-])=O)CP(O)([O-])=O)CP(O)([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C6H17N2O12P4Sm</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C6H20N2O12P4.Sm/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20;/h1-6H2,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20);/q;+3/p-3/i;1+3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>JSTADIGKFYFAIY-GJNDDOAHSA-K</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>245.09</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>76.95</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>31.44</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>11</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>0.96</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20502</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>76962714</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827722</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>143933</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Samarium_(153Sm)_lexidronam</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>